Evidence map›Paper›PMID 29047379›Full record

ArticleHealth and quality of life outcomes2017

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.

Massimo Breccia, Michele Baccarani, Gianantonio Rosti, Francesco Cottone, Laura Cannella, François Guilhot, Marco Vignetti, Fabio Efficace

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Health and quality of life outcomes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Massimo BrecciaDepartment of Biotechnologies and Hematology, University of Rome Sapienza, Rome, Italy.
Michele BaccaraniDepartment of Hematology-Oncology, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.
Gianantonio RostiDepartment of Hematology-Oncology, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.
Francesco CottoneItalian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Laura CannellaItalian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
François GuilhotInserm CIC 1402 , CHU de Poitiers, Poitiers, France.
Marco VignettiItalian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Fabio EfficaceItalian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy. f.efficace@gimema.it.
Fondazione Gimema Onlus · ITPoliclinico S.Orsola-Malpighi · ITCentre Hospitalier Universitaire de Poitiers · FRSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated factors that physicians consider of most importance in the selection of second line tyrosine kinase inhibitors treatments (TKIs) in chronic myeloid leukemia patients (CML).

Indexed as

Attitude of Health PersonnelQuality of LifeAntineoplastic AgentsDasatinibHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein-Tyrosine KinasesPyrimidinesAntineoplastic AgentsDasatinibnilotinibProtein-Tyrosine KinasesPyrimidinesChronic myeloid leukemiaLine of therapyTyrosine Kinase inhibitors

Identifiers

PMID29047379
PMCPMC5648464
OpenAlexW2767142280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.